- Home
- ATNM vs RPTX Comparison
ATNM vs RPTX Comparison
Compare ATNM & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- RPTX
- Stock Information
- Founded
- ATNM 2000
- RPTX 2016
- Country
- ATNM United States
- RPTX Canada
- Employees
- ATNM N/A
- RPTX N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- ATNM Health Care
- RPTX Health Care
- Exchange
- ATNM Nasdaq
- RPTX Nasdaq
- Market Cap
- ATNM 51.5M
- RPTX 58.8M
- IPO Year
- ATNM N/A
- RPTX 2020
- Fundamental
- Price
- ATNM $1.54
- RPTX $1.37
- Analyst Decision
- ATNM Strong Buy
- RPTX Strong Buy
- Analyst Count
- ATNM 3
- RPTX 3
- Target Price
- ATNM $4.67
- RPTX $4.50
- AVG Volume (30 Days)
- ATNM 229.8K
- RPTX 190.7K
- Earning Date
- ATNM 05-09-2025
- RPTX 05-13-2025
- Dividend Yield
- ATNM N/A
- RPTX N/A
- EPS Growth
- ATNM N/A
- RPTX N/A
- EPS
- ATNM N/A
- RPTX N/A
- Revenue
- ATNM N/A
- RPTX $1,073,000.00
- Revenue This Year
- ATNM N/A
- RPTX N/A
- Revenue Next Year
- ATNM N/A
- RPTX N/A
- P/E Ratio
- ATNM N/A
- RPTX N/A
- Revenue Growth
- ATNM N/A
- RPTX N/A
- 52 Week Low
- ATNM $1.03
- RPTX $0.89
- 52 Week High
- ATNM $8.64
- RPTX $4.29
- Technical
- Relative Strength Index (RSI)
- ATNM 49.81
- RPTX 55.96
- Support Level
- ATNM $1.56
- RPTX $1.33
- Resistance Level
- ATNM $1.69
- RPTX $1.41
- Average True Range (ATR)
- ATNM 0.11
- RPTX 0.07
- MACD
- ATNM -0.01
- RPTX -0.01
- Stochastic Oscillator
- ATNM 32.18
- RPTX 55.56
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.